Genmab A/S
GMAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434265
No open-market purchases or sales by Genmab A/S insiders were filed in the last 90 days; 291 institutions reported holding it in 13F filings for Q2 2026, worth $2.81B in total; no superinvestor holds it.
Other share classesGNMSF
Q2 2026 vs. Q1 2026
How the institutions holding Genmab A/S changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 275 | 3 | 291 | +19 |
| Shares | 81.8M | 54.7K | 102.3M | +20.5M (+25.1%) |
| Value | $2.23B | $1.47M | $2.81B | +$573.2M (+25.7%) |
3 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (49)
Institutions that held Genmab A/S at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (30)
Institutions that held Genmab A/S at the end of Q1 2026 and filed for Q2 2026 without it.
Not filed for Q2 2026 yet (3)
Institutions that held Genmab A/S at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Skopos Labs, Inc. | 35,823 | $961.1K |
| DGS Capital Management, LLC | 10,173 | $272.9K |
| CWM, LLC | 8,668 | $232.6K |